# Beyond Epilepsy Control: Repurposing Antiepileptic Drugs in CNS Tumor Therapy > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/antiepileptic-drugs-cns-tumor-therapy-repurposing/ > **Published:** 2026-03-24T20:05:48-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:40:01-04:00 > **Clinical Summary:** Explore antiepileptic drugs CNS tumor therapy potential beyond seizure control, highlighting emerging evidence for brain tumor treatment. --- CED Clinical Relevance  #60Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. 🔬 Evidence Watch  |  CED Clinic CbdEpilepsyCancerCnsReview Journal Cells Study Type [Clinical Study](https://cedclinic.com/cannabis-hyperemesis-syndrome-psychiatric-risk/) Population Human participants Why This Matters This review positions cannabidiol alongside established antiepileptic drugs as having potential direct antitumor activity in CNS malignancies, independent of [seizure control](https://cedclinic.com/portable-eeg-epilepsy-monitoring-seizure-detection-dogs/). For clinicians managing brain tumor patients already receiving CBD for seizures or other indications, this suggests possible additional therapeutic value beyond the primary indication. Clinical Summary This is a comprehensive review examining antiepileptic drugs, including cannabidiol, for direct antitumor effects in central nervous system cancers. The authors analyze mechanisms including metabolic reprogramming, epigenetic changes, cellular stress responses, and immune microenvironment modulation. While the review synthesizes promising preclinical data, it primarily draws from laboratory studies rather than controlled [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/). The [clinical evidence](https://cedclinic.com/academic-partnerships-cannabis-research/) for direct antitumor effects remains limited, particularly for cannabidiol in this context. Dr. Caplan’s Take “I find the mechanistic framework compelling, but we lack the clinical trial data needed to change practice. Until we have properly designed studies demonstrating improved tumor outcomes with cannabidiol as an adjuvant therapy, this remains an interesting hypothesis rather than actionable [clinical evidence](https://cedclinic.com/academic-partnerships-cannabis-research/).” Clinical Perspective 🧠 Clinicians should continue standard-of-care approaches for CNS tumors while remaining aware of this emerging research direction. Patients currently using cannabidiol for [seizure control](https://cedclinic.com/portable-eeg-epilepsy-monitoring-seizure-detection-dogs/) or other established indications may derive additional benefit, but we cannot yet recommend CBD specifically for antitumor effects. Future [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) will be essential to validate these laboratory findings. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Beyond%20Epilepsy%20Control%3A%20Repurposing%20Antiepileptic%20Drugs%20in%20Central%20Nervous%20Syst...%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/41827842/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/41827842/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Beyond%20Epilepsy%20Control%3A%20Repurposing%20Antiepileptic%20Drugs%20in%20Central%20Nervous%20Syst...%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/41827842/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41827842/](https://pubmed.ncbi.nlm.nih.gov/41827842/) Table of Contents - [FAQ](#FAQ)[Do antiepileptic drugs have direct anticancer effects beyond seizure control in CNS tumor patients?](#Do_antiepileptic_drugs_have_direct_anticancer_effects_beyond_seizure_control_in_CNS_tumor_patients) - [Which antiepileptic drugs show the most promise for CNS tumor therapy?](#Which_antiepileptic_drugs_show_the_most_promise_for_CNS_tumor_therapy) - [How do AEDs exert their antitumor effects at the cellular level?](#How_do_AEDs_exert_their_antitumor_effects_at_the_cellular_level) - [Can cannabidiol be considered as an adjuvant therapy for CNS tumors?](#Can_cannabidiol_be_considered_as_an_adjuvant_therapy_for_CNS_tumors) - [What is the clinical significance of AEDs affecting the tumor immune microenvironment?](#What_is_the_clinical_significance_of_AEDs_affecting_the_tumor_immune_microenvironment) - [Related](#Related) ## FAQ #### Do antiepileptic drugs have direct anticancer effects beyond seizure control in CNS tumor patients? Yes, emerging clinical evidence indicates that antiepileptic drugs (AEDs) possess direct antitumor activity independent of their seizure control mechanisms. These effects include metabolic reprogramming, epigenetic regulation, and modulation of the tumor immune microenvironment in CNS tumors. #### Which antiepileptic drugs show the most promise for CNS tumor therapy? Classic AEDs like valproic acid and levetiracetam, as well as novel agents like cannabidiol (CBD), demonstrate significant antitumor potential. These drugs target multiple pathways including ion homeostasis, endoplasmic reticulum stress responses, and tumor metabolism. #### How do AEDs exert their antitumor effects at the cellular level? AEDs work through multiple mechanisms including metabolic reprogramming of cancer cells, epigenetic modifications, induction of endoplasmic reticulum stress and unfolded protein response (ERS-UPR), and disruption of ion homeostasis. These multitarget effects make them particularly promising for combination therapies. #### Can cannabidiol be considered as an adjuvant therapy for CNS tumors? Based on this research, cannabidiol shows promise as a novel AED with antitumor properties for CNS malignancies. Its dual role in seizure control and direct tumor inhibition makes it an attractive candidate for further clinical investigation in neuro-oncology. #### What is the clinical significance of AEDs affecting the tumor immune microenvironment? AEDs’ ability to modulate the tumor immune microenvironment (TIME) suggests they could enhance immunotherapy responses in CNS tumor patients. This represents a novel therapeutic avenue that could improve outcomes beyond traditional seizure management in neuro-oncology practice. {“@context”: “https://schema.org”, “@type”: “ScholarlyArticle”, “headline”: “Beyond Epilepsy Control: Repurposing Antiepileptic Drugs in Central Nervous System Tumor Therapy.”, “url”: “https://pubmed.ncbi.nlm.nih.gov/41827842/”, “about”: “cells [clinical study](https://cedclinic.com/cannabis-hyperemesis-syndrome-psychiatric-risk/) beyond epilepsy control”, “isPartOf”: “Cells”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Beyond Epilepsy Control: Repurposing Antiepileptic Drugs in Central Nervous System Tumor Therapy.](https://cedclinic.com/cannabidiol-brain-tumor-antiepileptic-mechanisms-review/) A detailed review of cannabidiol and other antiepileptic drugs showing potential antitumor mechanisms in brain tumors. [Read the full review](https://cedclinic.com/cannabidiol-brain-tumor-antiepileptic-mechanisms-review/) [Almost – CBD and THC did more than just affect ovarian cancer cells in the lab.](https://cedclinic.com/preclinical-cancer-research-cannabinoids-cbd-thc-effects/) Research exploring the broader anticancer effects of cannabinoids beyond epilepsy and CNS tumors. [Explore cannabinoid research](https://cedclinic.com/preclinical-cancer-research-cannabinoids-cbd-thc-effects/) [The future of cancer research may lie in tricking the immune system, UT researchers say](https://cedclinic.com/cancer-immunotherapy-drug-interactions-ut-research/) Insights into novel cancer therapies focusing on [immune system](https://cedclinic.com/fungal-contamination-cannabis-risks-arizona-preroll-recall/) modulation relevant to CNS tumor treatment. [Learn about immune therapies](https://cedclinic.com/cancer-immunotherapy-drug-interactions-ut-research/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).